Progress in vaccine development for infectious diseases-a Keystone Symposia report.
antigen design
mRNA vaccines
structural vaccinology
vaccine delivery
vaccine hesitancy
vaccines
Journal
Annals of the New York Academy of Sciences
ISSN: 1749-6632
Titre abrégé: Ann N Y Acad Sci
Pays: United States
ID NLM: 7506858
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
medline:
23
6
2023
pubmed:
7
4
2023
entrez:
6
4
2023
Statut:
ppublish
Résumé
The COVID-19 pandemic has taught us many things, among the most important of which is that vaccines are one of the cornerstones of public health that help make modern longevity possible. While several different vaccines have been successful at stemming the morbidity and mortality associated with various infectious diseases, many pathogens/diseases remain recalcitrant to the development of effective vaccination. Recent advances in vaccine technology, immunology, structural biology, and other fields may yet yield insight that will address these diseases; they may also help improve societies' preparedness for future pandemics. On June 1-4, 2022, experts in vaccinology from academia, industry, and government convened for the Keystone symposium "Progress in Vaccine Development for Infectious Diseases" to discuss state-of-the-art technologies, recent advancements in understanding vaccine-mediated immunity, and new aspects of antigen design to aid vaccine effectiveness.
Substances chimiques
Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
65-86Subventions
Organisme : NIAID NIH HHS
ID : U19 AI167903
Pays : United States
Informations de copyright
© 2023 New York Academy of Sciences.
Références
World Health Organization. (2018). https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
Immunization. (2023). https://www.unicef.org/immunization
National Academies of Sciences, Engineering & Medicine. (2017). Integrating clinical research into epidemic response: The Ebola experience. Washgint, DC: The National Academies Press. https://doi.org/10.17226/24739
Graham, B. S., & Corbett, K. S. (2020). Prototype pathogen approach for pandemic preparedness: World on fire. Journal of Clinical Investigation, 130, 3348-3349.
Graham, B. S., & Sullivan, N. J. (2018). Emerging viral diseases from a vaccinology perspective: Preparing for the next pandemic. Nature Immunology, 19, 20-28.
Mclellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., Zhou, T., Graepel, K. W., Kumar, A., Moin, S., Boyington, J. C., Chuang, G.-Y., Soto, C., Baxa, U., Bakker, A. Q., … Kwong, P. D. (2013). Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science, 342, 592-598.
Mclellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., Kumar, A., Modjarrad, K., Zheng, Z., Zhao, M., Xia, N., Kwong, P. D., & Graham, B. S. (2013). Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science, 340, 1113-1117.
Graham, B. S., Gilman, M. S. A., & Mclellan, J. S. (2019). Structure-based vaccine antigen design. Annual Review of Medicine, 70, 91-104.
Kirchdoerfer, R. N., Cottrell, C. A., Wang, N., Pallesen, J., Yassine, H. M., Turner, H. L., Corbett, K. S., Graham, B. S., Mclellan, J. S., & Ward, A. B. (2016). Pre-fusion structure of a human coronavirus spike protein. Nature, 531, 118-121.
Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., Kong, W.-P., Andres, E. L., Kettenbach, A. N., Denison, M. R., Chappell, J. D., Graham, B. S., Ward, A. B., & Mclellan, J. S. (2017). Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proceedings of the National Academy of Sciences of the United States of America, 114, E7348-E7357.
Nelson, J., Sorensen, E. W., Mintri, S., Rabideau, A. E., Zheng, W., Besin, G., Khatwani, N., Su, S. V., Miracco, E. J., Issa, W. J., Hoge, S., Stanton, M. G., & Joyal, J. L. (2020). Impact of mRNA chemistry and manufacturing process on innate immune activation. Science Advances, 6, eaaz6893.
Dimitriadis, G. J. (1978). Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes. Nature, 274, 923-924.
Ostro, M. J., Giacomoni, D., Lavelle, D., Paxton, W., & Dray, S. (1978). Evidence for translation of rabbit globin mRNA after liposome-mediated insertion into a human cell line. Nature, 274, 921-923.
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990). Direct gene transfer into mouse muscle in vivo. Science, 247, 1465-1468.
Jirikowski, G. F., Sanna, P. P., Maciejewski-Lenoir, D., & Bloom, F. E. (1992). Reversal of diabetes insipidus in Brattleboro rats: Intrahypothalamic injection of vasopressin mRNA. Science, 255, 996-998.
Martinon, F., Krishnan, S., Lenzen, G., Magné, R., Gomard, E., Guillet, J. -G., Lévy, J.-P., & Meulien, P. (1993). Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. European Journal of Immunology, 23, 1719-1722.
Zhou, X., Berglund, P., Rhodes, G., Parker, S. E, Jondal, M., & Liljeström, P. (1994). Self-replicating semliki forest virus RNA as recombinant vaccine. Vaccine, 12, 1510-1514.
Conry, R. M., LoBuglio, A. F., Wright, M., Sumerel, L., Pike, M. J., Johanning, F., Benjamin, R., Lu, D., & Curiel, D. T. (1995). Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Research, 55, 1397-1400.
Boczkowski, D., Nair, S. K., Snyder, D., & Gilboa, E. (1996). Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. Journal of Experimental Medicine, 184, 465-472.
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021). Lipid nanoparticles for mRNA delivery. Nature Reviews Materials, 6, 1078-1094.
Weissman, D., Ni, H., Scales, D., Dude, A., Capodici, J., McGibney, K., Abdool, A., Isaacs, S. N., Cannon, G., & Karikó, K. (2000). HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. Journal of Immunology, 165, 4710-4717.
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005). Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23, 165-175.
Pardi, N., & Weissman, D. (2017). Nucleoside modified mRNA vaccines for infectious diseases. Methods in Molecular Biology, 1499, 109-121.
Sahin, U., Karikó, K., & Türeci, Ö. (2014). mRNA-based therapeutics-Developing a new class of drugs. Nature Reviews Drug Discovery, 13, 759-780.
Barbier, A J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022). The clinical progress of mRNA vaccines and immunotherapies. Nature Biotechnology, 40, 840-854.
Hotz, C., Wagenaar, T. R., Gieseke, F., Bangari, D. S., Callahan, M., Cao, H., Diekmann, J., Diken, M., Grunwitz, C., Hebert, A., Hsu, K., Bernardo, M., Karikó, K., Kreiter, S., Kuhn, A. N., Levit, M., Malkova, N., Masciari, S., Pollard, J., … Wiederschain, D. (2021). Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Science Translational Medicine, 13, eabc7804.
Stadler, C. R., Bähr-Mahmud, H., Celik, L., Hebich, B., Roth, A. S., Roth, R. P., Karikó, K., Türeci, Ö., & Sahin, U. (2017). Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nature Medicine, 23, 815-817.
The Janssen Ad26.COV2.S COVID-19 vaccine: What you need to know. (2022). https://www.who.int/news-room/feature-stories/detail/the-j-j-covid-19-vaccine-what-you-need-to-know
Abbink, P., Lemckert, A. A. C., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A. R., O'brien, K. L., Carville, A., Mansfield, K. G., Goudsmit, J., Havenga, M. J. E., & Barouch, D. H. (2007). Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. Journal of Virology, 81, 4654-4663.
Custers, J., Kim, D., Leyssen, M., Gurwith, M., Tomaka, F., Robertson, J., Heijnen, E., Condit, R., Shukarev, G., Heerwegh, D., Van Heesbeen, R., Schuitemaker, H., Douoguih, M., Evans, E., Smith, E. R., & Chen, R. T. (2021). Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment. Vaccine, 39, 3081-3101.
Salisch, N. C., Stephenson, K. E., Williams, K., Cox, F., Van Der Fits, L., Heerwegh, D., Truyers, C., Habets, M. N., Kanjilal, D. G., Larocca, R. A., Abbink, P., Liu, J., Peter, L., Fierro, C., De La Barrera, R. A., Modjarrad, K., Zahn, R. C., Hendriks, J., Cahill, C. P., … Barouch, D. H. (2021). A double-blind, randomized, placebo-controlled phase 1 study of Ad26.ZIKV.001, an Ad26-vectored anti-zika virus vaccine. Annals of Internal Medicine, 174, 585-594.
Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., Offergeld, K., Scheper, G., Taylor, K. L., Robb, M. L., Treanor, J., Barouch, D. H., Stoddard, J., Ryser, M. F., Marovich, M. A., … Douoguih, M. (2021). Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New England Journal of Medicine, 384, 2187-2201.
Collier, A.-R. Y., Yu, J., Mcmahan, K., Liu, J., Chandrashekar, A., Maron, J. S., Atyeo, C., Martinez, D. R., Ansel, J. L., Aguayo, R., Rowe, M., Jacob-Dolan, C., Sellers, D., Barrett, J., Ahmad, K., Anioke, T., Vanwyk, H., Gardner, S., Powers, O., … Barouch, D. H. (2021). Differential kinetics of immune responses elicited by covid-19 vaccines. New England Journal of Medicine, 385, 2010-2012.
Zheutlin, A., Ott, M., Sun, R., Zemlianskaia, N., Rubel, M., Hayden, J., Neri, B., Kamath, T., Khan, N., Schneeweiss, S., & Sarsour, K. (2022). Durability of protection against COVID-19 breakthrough infections and severe disease by vaccines in the United States. 2022.01.05.22268648.
Rosenberg, E. S., Dorabawila, V., Easton, D., Bauer, U. E., Kumar, J., Hoen, R., Hoefer, D., Wu, M., Lutterloh, E., Conroy, M. B., Greene, D., & Zucker, H. A. (2022). Covid-19 vaccine effectiveness in New York State. New England Journal of Medicine, 386, 116-127.
Hachmann, N. P., Miller, J., Collier, A. Y., Ventura, J. D., Yu, J., Rowe, M., Bondzie, E. A., Powers, O., Surve, N., Hall, K., & Barouch, D. H. (2022). Neutralization escape by the SARS-CoV-2 Omicron variants BA.2.12.1 and BA.4/BA.5. New England Journal of Medicine, 387(1), 86-88.
Gray, G., Collie, S., Goga, A., Garrett, N., Champion, J., Seocharan, I., Bamford, L., Moultrie, H., & Bekker, L.-G. (2022). Effectiveness of Ad26.COV2.S and BNT162b2 vaccines against Omicron variant in South Africa. New England Journal of Medicine, 386, 2243-2245.
Grifoni, A., Sidney, J., Vita, R., Peters, B., Crotty, S., Weiskopf, D., & Sette, A. (2021). SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19. Cell Host Microbe, 29, 1076-1092.
Liu, J., Chandrashekar, A., Sellers, D., Barrett, J., Jacob-Dolan, C., Lifton, M., Mcmahan, K., Sciacca, M., Vanwyk, H., Wu, C., Yu, J., Collier, A.-R. Y., & Barouch, D. H. (2022). Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature, 603, 493-496.
Chandrashekar, A., Yu, J., Mcmahan, K., Jacob-Dolan, C., Liu, J., He, X., Hope, D., Anioke, T., Barrett, J., Chung, B., Hachmann, N. P., Lifton, M., Miller, J., Powers, O., Sciacca, M., Sellers, D., Siamatu, M., Surve, N., Vanwyk, H., … Barouch, D. H. (2022). Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. Cell, 185, 1549-1555.e11.e11.
Koup, R. A., Donis, R. O., Gilbert, P. B., Li, A. W., Shah, N. A., & Houchens, C. R. (2021). A government-led effort to identify correlates of protection for COVID-19 vaccines. Nature Medicine, 27, 1493-1494.
Gilbert, P. B., Montefiori, D. C., Mcdermott, A. B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., Castellino, F., Flach, B., Lin, B. C., O'connell, S., Mcdanal, C., Eaton, A., Sarzotti-Kelsoe, M., Lu, Y., Yu, C., … Koup, R. A. (2022). Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 375, 43-50.
Fong, Y., McDermott, A. B., Benkeser, D., Roels, S., Stieh, D. J., Vandebosch, A., Gars, M. L., Van Roey, G. A., Houchens, C. R., Martins, K., Jayashankar, L., Castellino, F., Amoa-Awua, O., Basappa, M., Flach, B., Lin, B. C., Moore, C., Naisan, M., Naqvi, M., … Donis, R. O. (2022). Immune correlates analysis of a single Ad26.COV2.S dose in the ENSEMBLE COVID-19 vaccine efficacy clinical trial. 2022.04.06.22272763.
Atmar, R. L., Lyke, K. E., Deming, M. E., Jackson, L. A., Branche, A. R., El Sahly, H. M., Rostad, C. A., Martin, J. M., Johnston, C., Rupp, R. E., Mulligan, M. J., Brady, R. C., Frenck, R. W., Bäcker, M., Kottkamp, A. C., Babu, T. M., Rajakumar, K., Edupuganti, S., Dobrzynski, D., … Beigel, J. H. (2022). Homologous and heterologous covid-19 booster vaccinations. New England Journal of Medicine, 386, 1046-1057.
Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O'dell, S., Mcdanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., Tang, H., Manning, K. E., Edara, V.- V., Lai, L., Ellis, M., Moore, K. M., Floyd, K., Foster, S. L., Posavad, C. M., … Montefiori, D. C. (2022). SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. New England Journal of Medicine, 386, 1088-1091.
Schwendinger, M., Thiry, G., De Vos, B., Leroux-Roels, G., Bruhwyler, J., Huygens, A., Ganeff, C., Buchinger, H., Orlinger, K. K., Pinschewer, D. D., Monath, T. P., & Lilja, A. E. (2022). A randomized dose-escalating phase I trial of a replication-deficient lymphocytic choriomeningitis virus vector-based vaccine against human cytomegalovirus. Journal of Infectious Diseases, 225, 1399-1410.
Janes, H., Friedrich, D. P., Krambrink, A., Smith, R. J., Kallas, E. G., Horton, H., Casimiro, D. R., Carrington, M., Geraghty, D. E., Gilbert, P. B., Mcelrath, M. J., & Frahm, N. (2013). Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection. Journal of Infectious Diseases, 208, 1231-1239.
Collins, D. R., Gaiha, G. D., & Walker, B. D. (2020). CD8+ T cells in HIV control, cure and prevention. Nature Reviews Immunology, 20, 471-482.
Barouch, D. H., Liu, J., Li, H., Maxfield, L. F., Abbink, P., Lynch, D. M., Iampietro, M. J., Sanmiguel, A., Seaman, M. S., Ferrari, G., Forthal, D. N., Ourmanov, I., Hirsch, V. M., Carville, A., Mansfield, K. G., Stablein, D., Pau, M. G., Schuitemaker, H., Sadoff, J. C., … Michael, N. L. (2012). Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature, 482, 89-93.
Boopathy, A. V., Sharma, B., Deutschmann, D., Truong, H., Lee, J., Murry, J., Callebaut, C., Geleziunas, R., Blair, W., Orlinger, K., Schmidt, S., Lauterbach, H., Makadzange, T., & Ahmadi-Erbe, S. (2022). Immunogenicity and prophylactic efficacy of arenavirus-based SIV vaccine in macaques. CROI Poster.
Kremsner, P. G., Ahuad Guerrero, R. A., Arana-Arri, E., Aroca Martinez, G. J., Bonten, M., Chandler, R., Corral, G., De Block, E. J. L., Ecker, L., Gabor, J. J., Garcia Lopez, C. A., Gonzales, L., Granados González, M. A., Gorini, N., Grobusch, M. P., Hrabar, A. D., Junker, H., Kimura, A., Lanata, C. F., … Quintini, G. (2022). Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): A randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. Lancet Infectious Diseases, 22, 329-340.
Liu, Y., & Ye, Q. (2022). Safety and efficacy of the common vaccines against COVID-19. Vaccines, 10, 513.
Hoffmann, D., Corleis, B., Rauch, S., Roth, N., Mühe, J., Halwe, N. J., Ulrich, L., Fricke, C., Schön, J., Kraft, A., Breithaupt, A., Wernike, K., Michelitsch, A., Sick, F., Wylezich, C., Hoffmann, B., Thran, M., Thess, A., Mueller, S. O., … Beer, M. (2021). CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2. Nature Communications, 12, 4048.
Gebre, M. S., Rauch, S., Roth, N., Yu, J., Chandrashekar, A., Mercado, N. B., He, X., Liu, J., McMahan, K., Martinot, A., Martinez, D. R., Giffin, V., Hope, D., Patel, S., Sellers, D., Sanborn, O., Barrett, J., Liu, X., Cole, A. C., … Barouch, D. H. (2022). Optimization of non-coding regions improves protective efficacy of an mRNA SARS-CoV-2 vaccine in nonhuman primates. Nature, 601(7893), 410-414.
Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S O., Petsch, B., & Rauch, S. (2021). CV2CoV, an enhanced mRNA-based SARS-CoV-2 vaccine candidate, supports higher protein expression and improved immunogenicity in rats. 2021.05.13.443734.
GlaxoSmithKline. (2022). A phase 1, open-label, safety, reactogenicity, and immunogenicity trial of the CV2CoV mRNA vaccine against SARS CoV 2 in seropositive adult participants. clinicaltrials.gov
Freyn, A. W., Ramos Da Silva, J., Rosado, V. C., Bliss, C. M., Pine, M., Mui, B. L., Tam, Y. K., Madden, T. D., De Souza Ferreira, L. C., Weissman, D., Krammer, F., Coughlan, L., Palese, P., Pardi, N., & Nachbagauer, R. (2020). A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Molecular Therapy, 28, 1569-1584.
Moderna announces first participants dosed in phase 3 study of seasonal influenza vaccine candidate (mRNA-1010). (2022). https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-First-Participants-Dosed-in-Phase-3-Study-of-Seasonal-Influenza-Vaccine-Candidate-mRNA-1010/default.aspx
Nachbagauer, R., & Palese, P. (2020). Is a universal influenza virus vaccine possible? Annual Review of Medicine, 71, 315-327.
Krammer, F. (2019). The human antibody response to influenza A virus infection and vaccination. Nature Reviews Immunology, 19, 383-397.
Turner, J. S., Zhou, J. Q., Han, J., Schmitz, A. J., Rizk, A. A., Alsoussi, W. B., Lei, T., Amor, M., Mcintire, K. M., Meade, P., Strohmeier, S., Brent, R. I., Richey, S. T., Haile, A., Yang, Y. R., Klebert, M. K., Suessen, T., Teefey, S., Presti, R. M., … Ellebedy, A. H. (2020). Human germinal centres engage memory and naive B cells after influenza vaccination. Nature, 586, 127-132.
Kim, W., Zhou, J. Q., Horvath, S. C., Schmitz, A. J., Sturtz, A. J., Lei, T., Liu, Z., Kalaidina, E., Thapa, M., Alsoussi, W. B., Haile, A., Klebert, M. K., Suessen, T., Parra-Rodriguez, L., Mudd, P. A., Whelan, S. P. J., Middleton, W. D., Teefey, S. A., Pusic, I., … Ellebedy, A. H. (2022). Germinal centre-driven maturation of B cell response to mRNA vaccination. Nature, 604, 141-145.
Liang, F., Lindgren, G., Lin, A., Thompson, E. A., Ols, S., Röhss, J., John, S., Hassett, K., Yuzhakov, O., Bahl, K., Brito, L. A., Salter, H., Ciaramella, G., & Loré, K. (2017). Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Molecular Therapy, 25, 2635-2647.
Liang, F., Lindgren, G., Sandgren, K. J., Thompson, E. A., Francica, J. R., Seubert, A., De Gregorio, E., Barnett, S., O'hagan, D. T., Sullivan, N. J., Koup, R. A., Seder, R. A., & Loré, K. (2017). Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Science Translational Medicine, 9, eaal2094.
Ols, S., Yang, L., Thompson, E. A., Pushparaj, P., Tran, K., Liang, F., Lin, A., Eriksson, B., Karlsson Hedestam, G. B., Wyatt, R. T., & Loré, K. (2020). Route of vaccine administration alters antigen trafficking but not innate or adaptive immunity. Cell Reports, 30, 3964-3971.e7.e7.
Tokatlian, T., Read, B. J., Jones, C. A., Kulp, D. W., Menis, S., Chang, J. Y. H., Steichen, J. M., Kumari, S., Allen, J. D., Dane, E. L., Liguori, A., Sangesland, M., Lingwood, D., Crispin, M., Schief, W. R., & Irvine, D. J. (2019). Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. Science, 363, 649-654.
Read, B. J., Won, L., Kraft, J. C., Sappington, I., Aung, A., Wu, S., Bals, J., Chen, C., Lee, K. K., Lingwood, D., King, N. P., & Irvine, D. J. (2022). Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens. Cell Reports, 38, 110217.
Tam, H. H., Melo, M. B., Kang, M., Pelet, J. M., Ruda, V. M., Foley, M. H., Hu, J. K., Kumari, S., Crampton, J., Baldeon, A. D., Sanders, R. W., Moore, J. P., Crotty, S., Langer, R., Anderson, D. G., Chakraborty, A. K., & Irvine, D. J. (2016). Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proceedings of the National Academy of Sciences of the United States of America, 113, E6639-E6648.
Cirelli, K. M., Carnathan, D. G., Nogal, B., Martin, J. T., Rodriguez, O. L., Upadhyay, A. A., Enemuo, C. A., Gebru, E. H., Choe, Y., Viviano, F., Nakao, C., Pauthner, M. G., Reiss, S., Cottrell, C. A., Smith, M. L., Bastidas, R., Gibson, W., Wolabaugh, A. N., Melo, M. B., … Crotty, S. (2019). Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of immunodominance. Cell, 177, 1153-1171.e28.e28.
Moyer, T. J., Kato, Y., Abraham, W., Chang, J. Y. H., Kulp, D. W., Watson, N., Turner, H. L., Menis, S., Abbott, R. K., Bhiman, J. N., Melo, M. B., Simon, H. A., Herrera-De La Mata, S., Liang, S., Seumois, G., Agarwal, Y., Li, N., Burton, D. R., Ward, A. B., … Irvine, D. J. (2020). Engineered immunogen binding to alum adjuvant enhances humoral immunity. Nature Medicine, 26, 430-440.
Rodrigues, K. A., Rodriguez-Aponte, S. A., Dalvie, N. C., Lee, J. H., Abraham, W., Carnathan, D. G., Jimenez, L. E., Ngo, J. T., Chang, J. Y. H., Zhang, Z., Yu, J., Chang, A., Nakao, C., Goodwin, B., Naranjo, C. A., Zhang, L., Silva, M., Barouch, D. H., Silvestri, G., … Irvine, D. J. (2021). Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2. Science Advances, 7, eabj6538.
Silva, M., Kato, Y., Melo, M. B., Phung, I., Freeman, B. L., Li, Z., Roh, K., Van Wijnbergen, J. W., Watkins, H., Enemuo, C. A., Hartwell, B. L., Chang, J. Y. H., Xiao, S., Rodrigues, K. A., Cirelli, K. M., Li, N., Haupt, S., Aung, A., Cossette, B., … Irvine, D. J. (2021). A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity. Science Immunology, 6, eabf1152.
Aung, A., Cui, A., Maiorino, L., Amini, A. P., Gregory, J. R., Bukenya, M., Zhang, Y., Lee, H., Cottrell, C. A., Morgan, D. M., Silva, M., Suh, H., Kirkpatrick, J. D., Amlashi, P., Remba, T., Froehle, L. M., Xiao, S., Abraham, W., Adams, J., … Irvine, D. J. (2023). Low protease activity in B cell follicles promotes retention of intact antigens after immunization. Science, 379(6630), eabn8934.
Soleimany, A. P., Kirkpatrick, J. D., Su, S., Dudani, J. S., Zhong, Q., Bekdemir, A., & Bhatia, S. N. (2021). Activatable zymography probes enable in situ localization of protease dysregulation in cancer. Cancer Research, 81, 213-224.
Martin, J. T., Cottrell, C. A., Antanasijevic, A., Carnathan, D. G., Cossette, B. J., Enemuo, C. A., Gebru, E. H., Choe, Y., Viviano, F., Fischinger, S., Tokatlian, T., Cirelli, K. M., Ueda, G., Copps, J., Schiffner, T., Menis, S., Alter, G., Schief, W. R., Crotty, S., … Irvine, D. J. (2020). Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations. NPJ Vaccines, 5, 72.
Martin, J. T., Hartwell, B. L., Kumarapperuma, S. C., Melo, M. B., Carnathan, D. G., Cossette, B. J., Adams, J., Gong, S., Zhang, W., Tokatlian, T., Menis, S., Schiffner, T., Franklin, C. G., Goins, B., Fox, P. T., Silvestri, G., Schief, W. R., Ruprecht, R. M., & Irvine, D. J. (2021). Combined PET and whole-tissue imaging of lymphatic-targeting vaccines in non-human primates. Biomaterials, 275, 120868.
Pilkington, E. H., Suys, E. J. A., Trevaskis, N. L., Wheatley, A. K., Zukancic, D., Algarni, A., Al-Wassiti, H., Davis, T. P., Pouton, C. W., Kent, S. J., & Truong, N. P. (2021). From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomaterialia, 131, 16-40.
Zukancic, D., Suys, E. J. A., Pilkington, E. H., Algarni, A., Al-Wassiti, H., & Truong, N. P. (2020). The importance of Poly(ethylene glycol) and lipid structure in targeted gene delivery to lymph nodes by lipid nanoparticles. Pharmaceutics, 12, 1068.
Algarni, A., Pilkington, E. H., Suys, E. J. A., Al-Wassiti, H., Pouton, C. W., & Truong, N. P. (2022). In vivo delivery of plasmid DNA by lipid nanoparticles: The influence of ionizable cationic lipids on organ-selective gene expression. Biomaterials Science, 10, 2940-2952.
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., Grunwitz, C., Vormehr, M., Hüsemann, Y., Selmi, A., Kuhn, A. N., Buck, J., Derhovanessian, E., Rae, R., Attig, S., … Sahin, U. (2016). Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature, 534, 396-401.
Tahtinen, S., Tong, A.-J., Himmels, P., Oh, J., Paler-Martinez, A., Kim, L., Wichner, S., Oei, Y., Mccarron, M. J., Freund, E. C., Amir, Z. A., De La Cruz, C. C., Haley, B., Blanchette, C., Schartner, J. M., Ye, W., Yadav, M., Sahin, U., Delamarre, L., & Mellman, I. (2022). IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nature Immunology, 23, 532-542.
Lee, A. R. Y. B., Wong, S. Y., Chai, L. Y. A., Lee, S. C., Lee, M. X., Muthiah, M. D., Tay, S. H., Teo, C. B., Tan, B. K. J., Chan, Y. H., Sundar, R., & Soon, Y. Y. (2022). Efficacy of covid-19 vaccines in immunocompromised patients: Systematic review and meta-analysis. BMJ, 376, e068632.
Karaba, A. H., Zhu, X., Liang, T., Wang, K. H., Rittenhouse, A. G., Akinde, O., Eby, Y., Ruff, J. E., Blankson, J. N., Abedon, A. T., Alejo, J. L., Cox, A. L., Bailey, J. R., Thompson, E. A., Klein, S. L., Warren, D. S., Garonzik-Wang, J. M., Boyarsky, B. J., Sitaras, I., … Werbel, W. A. (2022). A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients. American Journal of Transplantation, 22, 1253-1260.
Palgen, J.-L., Tchitchek, N., Rodriguez-Pozo, A., Jouhault, Q., Abdelhouahab, H., Dereuddre-Bosquet, N., Contreras, V., Martinon, F., Cosma, A., Lévy, Y., Le Grand, R., & Beignon, A.-S. (2020). Innate and secondary humoral responses are improved by increasing the time between MVA vaccine immunizations. NPJ Vaccines, 5, 24.
Feraoun, Y., Palgen, J.-L., Joly, C., Tchitchek, N., Marcos-Lopez, E., Dereuddre-Bosquet, N., Gallouet, A.-S., Contreras, V., Lévy, Y., Martinon, F., Le Grand, R., & Beignon, A.-S. (2021). The route of vaccine administration determines whether blood neutrophils undergo long-term phenotypic modifications. Frontiers in Immunology, 12, 784813.
Kanekiyo, M., Wei, C.-J., Yassine, H. M., Mctamney, P. M., Boyington, J. C., Whittle, J. R. R., Rao, S. S., Kong, W.-P., Wang, L., & Nabel, G. J. (2013). Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature, 499, 102-106.
Divine, R., Dang, H. V., Ueda, G., Fallas, J. A., Vulovic, I., Sheffler, W., Saini, S., Zhao, Y. T., Raj, I. X., Morawski, P. A., Jennewein, M. F., Homad, L J., Wan, Y.-H, Tooley, M. R., Seeger, F., Etemadi, A., Fahning, M. L., Lazarovits, J., Roederer, A., … Baker, D. (2021). Designed proteins assemble antibodies into modular nanocages. Science, 372, eabd9994.
King, N. P., Bale, J. B., Sheffler, W., Mcnamara, D. E., Gonen, S., Gonen, T., Yeates, T. O., & Baker, D. (2014). Accurate design of co-assembling multi-component protein nanomaterials. Nature, 510, 103-108.
Hsia, Y., Bale, J. B., Gonen, S., Shi, D., Sheffler, W., Fong, K. K., Nattermann, U., Xu, C., Huang, P.-S., Ravichandran, R., Yi, S., Davis, T. N., Gonen, T., King, N. P., & Baker, D. (2016). Design of a hyperstable 60-subunit protein dodecahedron. [corrected]. Nature, 535, 136-139.
Bale, J. B., Gonen, S., Liu, Y., Sheffler, W., Ellis, D., Thomas, C., Cascio, D., Yeates, T. O., Gonen, T., King, N. P., & Baker, D. (2016). Accurate design of megadalton-scale two-component icosahedral protein complexes. Science, 353, 389-394.
Ueda, G., Antanasijevic, A., Fallas, J. A., Sheffler, W., Copps, J., Ellis, D., Hutchinson, G. B., Moyer, A., Yasmeen, A., Tsybovsky, Y., Park, Y.-J., Bick, M. J., Sankaran, B., Gillespie, R. A., Brouwer, P. J., Zwart, P. H., Veesler, D., Kanekiyo, M., Graham, B. S., … Baker, D. (2020). Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. eLife, 9, e57659.
Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O'connor, M. A., Chen, C., Navarro, M. J., Miranda, M. C., Pettie, D., Ravichandran, R., Kraft, J. C., Ogohara, C., Palser, A., Chalk, S., Lee, E.-C., … King, N. P. (2020). Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell, 183, 1367-1382.e17.
Song, J. Y., Choi, W. S., Heo, J. Y., Lee, J. S., Jung, D. S., Kim, S.-W., Park, K.-H., Eom, J. S., Jeong, S. J., Lee, J., Kwon, K. T., Choi, H. J., Sohn, J. W., Kim, Y. K., Noh, J. Y., Kim, W. J., Roman, F., Ceregido, M. A., Solmi, F., …., Cheon, H. J. (2022). Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A phase 1/2, randomized, placebo-controlled, observer-blinded trial. EClinicalMedicine, 51, 101569.
SK Bioscience. (2022). https://www.skbioscience.co.kr/en/news/news_01_01?mode=view&id=132&
Marcandalli, J., Fiala, B., Ols, S., Perotti, M., de van der Schueren, W., Snijder, J., Hodge, E., Benhaim, M., Ravichandran, R., Carter, L., Sheffler, W., Brunner, L., Lawrenz, M., Dubois, P., Lanzavecchia, A., Sallusto, F., Lee, K. K., Veesler, D., Correnti, C. E., … King, N. P. (2019). Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell, 176, 1420-1431.e17.e17.
Wilson, J. T. (2019). A sweeter approach to vaccine design. Science, 363, 584-585.
Boyoglu-Barnum, S., Ellis, D., Gillespie, R. A., Hutchinson, G. B., Park, Y.-J., Moin, S. M., Acton, O. J., Ravichandran, R., Murphy, M., Pettie, D., Matheson, N., Carter, L., Creanga, A., Watson, M. J., Kephart, S., Ataca, S., Vaile, J. R., Ueda, G., Crank, M. C., … Kanekiyo, M. (2021). Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature, 592, 623-628.
Kanekiyo, M., Joyce, M. G., Gillespie, R. A., Gallagher, J. R., Andrews, S. F., Yassine, H. M., Wheatley, A. K., Fisher, B. E., Ambrozak, D. R., Creanga, A., Leung, K., Yang, E. S., Boyoglu-Barnum, S., Georgiev, I. S., Tsybovsky, Y., Prabhakaran, M. S., Andersen, H., Kong, W.-P., Baxa, U., … Graham, B. S. (2019). Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nature Immunology, 20, 362-372.
Burton, D. R., & Topol, E. J. (2021). Variant-proof vaccines - Invest now for the next pandemic. Nature, 590, 386-388.
Haynes, B. F., Kelsoe, G., Harrison, S. C., & Kepler, T. B. (2012). B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nature Biotechnology, 30, 423-433.
Wiehe, K., Bradley, T., Meyerhoff, R. R., Hart, C., Williams, W. B., Easterhoff, D., Faison, W. J., Kepler, T. B., Saunders, K. O., Alam, S. M., Bonsignori, M., & Haynes, B. F. (2018). Functional relevance of improbable antibody mutations for HIV broadly neutralizing antibody development. Cell Host Microbe, 23, 759-765.e6.e6.
Saunders, K. O., Wiehe, K., Tian, M., Acharya, P., Bradley, T., Alam, S. M., Go, E. P., Scearce, R., Sutherland, L., Henderson, R., Hsu, A. L., Borgnia, M. J., Chen, H., Lu, X., Wu, N. R., Watts, B., Jiang, C., Easterhoff, D., Cheng, H.-L., … Haynes, B. F. (2019). Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Science, 366, eaay7199.
Mu, Z., Wiehe, K., Saunders, K. O., Henderson, R., Cain, D. W., Parks, R., Martik, D., Mansouri, K., Edwards, R. J., Newman, A., Lu, X., Xia, S.-M., Eaton, A., Bonsignori, M., Montefiori, D., Han, Q., Venkatayogi, S., Evangelous, T., Wang, Y., … Haynes, B. F. (2022). mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Cell Reports, 38, 110514.
Zohar, T., Loos, C., Fischinger, S., Atyeo, C., Wang, C., Slein, M. D., Burke, J., Yu, J., Feldman, J., Hauser, B. M., Caradonna, T., Schmidt, A. G., Cai, Y., Streeck, H., Ryan, E. T., Barouch, D. H., Charles, R. C., Lauffenburger, D. A., & Alter, G. (2020). Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell, 183, 1508-1519.e12.e12.
Bartsch, Y. C., Denis, K. J. S., Kaplonek, P., Kang, J., Lam, E. C., Burns, M. D., Farkas, E. J., Davis, J. P., Boribong, B. P., Edlow, A. G., Fasano, A., Shreffler, W., Zavadska, D., Johnson, M., Goldblatt, D., Balazs, A. B., Yonker, L. M., & Alter, G. (2022). Comprehensive antibody profiling of mRNA vaccination in children. 2021.10.07.463592.
Puranik, A., Lenehan, P. J., Silvert, E., Niesen, M. J. M., Corchado-Garcia, J., O'Horo, J. C., Virk, A., Swift, M. D., Halamka, J., Badley, A. D., Venkatakrishnan, A. J., & Soundararajan, V. (2021). Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. 2021.08.06.21261707.
Kaplonek, P., Cizmeci, D., Fischinger, S., Collier, A.-R., Suscovich, T., Linde, C., Broge, T., Mann, C., Amanat, F., Dayal, D., Rhee, J., De St Aubin, M., Nilles, E. J., Musk, E. R., Menon, A. S., Saphire, E. O., Krammer, F., Lauffenburger, D. A., Barouch, D. H., & Alter, G. (2022). mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions. Science Translational Medicine, 14, eabm2311.
Nordström, P., Ballin, M., & Nordström, A. (2022). Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: A retrospective, total population cohort study in Sweden. Lancet Infectious Diseases, 22, 781-790.
Bowman, K. A., Stein, D., Shin, S., Ferbas, K. G., Tobin, N. H., Mann, C., Fischinger, S., Saphire, E. O., Lauffenburger, D., Rimoin, A. W., Aldrovandi, G., & Alter, G. (2022). Hybrid immunity shifts the Fc-effector quality of SARS-CoV-2 mRNA vaccine-induced immunity. mBio, 13(5), e016472.
Corbett, K. S., Moin, S. M., Yassine, H. M., Cagigi, A., Kanekiyo, M., Boyoglu-Barnum, S., Myers, S. I., Tsybovsky, Y., Wheatley, A. K., Schramm, C. A., Gillespie, R. A., Shi, W., Wang, L., Zhang, Y., Andrews, S. F., Joyce, M. G, Crank, M. C., Douek, D. C., Mcdermott, A. B., … Boyington, J. C. (2019). Design of nanoparticulate group 2 influenza virus hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages. mBio, 10(1), e02810-18.
Creanga, A., Gillespie, R. A., Fisher, B. E., Andrews, S. F., Lederhofer, J., Yap, C., Hatch, L., Stephens, T., Tsybovsky, Y., Crank, M. C., Ledgerwood, J. E., Mcdermott, A. B., Mascola, J. R., Graham, B. S., & Kanekiyo, M. (2021). A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies. Nature Communications, 12, 1722.
Yassine, H. M., Boyington, J. C., Mctamney, P. M., Wei, C.-J., Kanekiyo, M., Kong, W.-P., Gallagher, J. R., Wang, L., Zhang, Y., Joyce, M. G., Lingwood, D., Moin, S. M., Andersen, H., Okuno, Y., Rao, S. S., Harris, A. K., Kwong, P. D., Mascola, J. R., Nabel, G. J., & Graham, B. S. (2015). Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nature Medicine, 21, 1065-1070.
Moin, S. M., Boyington, J. C., Boyoglu-Barnum, S., Gillespie, R A., Cerutti, G., Cheung, C. S.-F., Cagigi, A., Gallagher, J R., Brand, J., Prabhakaran, M., Tsybovsky, Y., Stephens, T., Fisher, B E., Creanga, A., Ataca, S., Rawi, R., Corbett, K S., Crank, M C., Gorman, J., … Kanekiyo, M. (2022). Vaccine-elicitation of cross-group neutralizing protective antibodies to influenza A viruses. 2022.02.11.480115.
Fuerst, T. R., Pierce, B. G., Keck, Z.-Y., & Foung, S. K. H. (2018). Designing a B cell-based vaccine against a highly variable hepatitis C virus. Frontiers in Microbiology, 8, 2692.
Lavie, M., Hanoulle, X., & Dubuisson, J. (2018). Glycan shielding and modulation of hepatitis C virus neutralizing antibodies. Frontiers in Immunology, 9, 910.
Torrents De La Peña, A., Sliepen, K., Eshun-Wilson, L., Newby, M. L., Allen, J. D., Zon, I., Koekkoek, S., Chumbe, A., Crispin, M., Schinkel, J., Lander, G. C., Sanders, R. W., & Ward, A. B. (2022). Structure of the hepatitis C virus E1E2 glycoprotein complex. Science, 378(6617), 263-269.
Corcoran, M. M., Phad, G. E., Bernat, N. V., Stahl-Hennig, C., Sumida, N., Persson, M. A. A., Martin, M., & Karlsson Hedestam, G. B. (2016). Production of individualized V gene databases reveals high levels of immunoglobulin genetic diversity. Nature Communications, 7, 13642.
Sheward, D. J., Pushparaj, P., Das, H., Kim, C., Kim, S., Hanke, L., Dyrdak, R., McInerney, G., Albert, J., Murrell, B., Karlsson, G B., Karlsson Hedestam, G. B., & Hällberg, M. (2022). Structural basis of Omicron neutralization by affinity-matured public antibodies. 2022.01.03.474825.
Murugan, R., Scally, S. W., Costa, G., Mustafa, G., Thai, E., Decker, T., Bosch, A., Prieto, K., Levashina, E. A., Julien, J.-P., & Wardemann, H. (2020). Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs. Nature Medicine, 26, 1135-1145.
Pholcharee, T., Oyen, D., Flores-Garcia, Y., Gonzalez-Paez, G., Han, Z., Williams, K. L., Volkmuth, W., Emerling, D., Locke, E., Richter King, C., Zavala, F., & Wilson, I. A. (2021). Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against P. falciparum. Nature Communications, 12, 1063.
Gaudinski, M. R., Berkowitz, N. M., Idris, A. H., Coates, E. E., Holman, L. A., Mendoza, F., Gordon, I. J., Plummer, S. H., Trofymenko, O., Hu, Z., Campos Chagas, A., O'connell, S., Basappa, M., Douek, N., Narpala, S. R., Barry, C. R., Widge, A. T., Hicks, R., Awan, S. F., … Seder, R. A. (2021). A monoclonal antibody for malaria prevention. New England Journal of Medicine, 385, 803-814.
Scally, S. W., Murugan, R., Bosch, A., Triller, G., Costa, G., Mordmüller, B., Kremsner, P. G., Sim, B. K. L., Hoffman, S. L., Levashina, E. A., Wardemann, H., & Julien, J.-P. (2018). Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection. Journal of Experimental Medicine, 215, 63-75.
Wahl, I., Obraztsova, A. S., Puchan, J., Hundsdorfer, R., Chakravarty, S., Sim, B. K. L., Hoffman, S. L., Kremsner, P. G., Mordmüller, B., & Wardemann, H. (2022). Clonal evolution and TCR specificity of the human TFH cell response to Plasmodium falciparum CSP. Science Immunology, 7, eabm9644.
Pulendran, B., Li, S., & Nakaya, H. I. (2010). Systems vaccinology. Immunity, 33, 516-529.
Li, S., Sullivan, N. L., Rouphael, N., Yu, T., Banton, S., Maddur, M. S., Mccausland, M., Chiu, C., Canniff, J., Dubey, S., Liu, K., Tran, V., Hagan, T., Duraisingham, S., Wieland, A., Mehta, A. K., Whitaker, J. A., Subramaniam, S., Jones, D. P., … Pulendran, B. (2017). Metabolic phenotypes of response to vaccination in humans. Cell, 169, 862-877.e17.e17.
Nakaya, H. I., Wrammert, J., Lee, E. K., Racioppi, L., Marie-Kunze, S., Haining, W. N., Means, A. R., Kasturi, S. P., Khan, N., Li, G. M., Mccausland, M., Kanchan, V., Kokko, K. E., Li, S., Elbein, R., Mehta, A. K., Aderem, A., Subbarao, K., Ahmed, R., & Pulendran, B. (2011). Systems biology of vaccination for seasonal influenza in humans. Nature Immunology, 12, 786-795.
Nakaya, H. I., Hagan, T., Duraisingham, S. S., Lee, E. K., Kwissa, M., Rouphael, N., Frasca, D., Gersten, M., Mehta, A. K., Gaujoux, R., Li, G.-M., Gupta, S., Ahmed, R., Mulligan, M. J., Shen-Orr, S., Blomberg, B. B., Subramaniam, S., & Pulendran, B. (2015). Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures. Immunity, 43, 1186-1198.
Oh, J. Z., Ravindran, R., Chassaing, B., Carvalho, F. A., Maddur, M. S., Bower, M., Hakimpour, P., Gill, K. P., Nakaya, H. I., Yarovinsky, F., Sartor, R. B., Gewirtz, A. T., & Pulendran, B. (2014). TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination. Immunity, 41, 478-492.
Hagan, T., Cortese, M., Rouphael, N., Boudreau, C., Linde, C., Maddur, M. S., Das, J., Wang, H., Guthmiller, J., Zheng, N.-Y., Huang, M., Uphadhyay, A. A., Gardinassi, L., Petitdemange, C., Mccullough, M. P., Johnson, S. J., Gill, K., Cervasi, B., Zou, J., … Pulendran, B. (2019). Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans. Cell, 178, 1313-1328.e13.e13.
Suthar, M. S., Arunachalam, P. S., Hu, M., Reis, N., Trisal, M., Raeber, O., Chinthrajah, S., Davis-Gardner, M E., Manning, K., Mudvari, P., Boritz, E., Godbole, S., Henry, A R., Douek, D C., Halfmann, P., Kawaoka, Y., Zarnitsyna, V I., Nadeau, K., & Pulendran, B. (2021). Durability of immune responses to the BNT162b2 mRNA vaccine. 2021.09.30.462488.
Querec, T., Bennouna, S., Alkan, S., Laouar, Y., Gorden, K., Flavell, R., Akira, S., Ahmed, R., & Pulendran, B. (2006). Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. Journal of Experimental Medicine, 203, 413-424.
Querec, T. D., Akondy, R. S., Lee, E. K., Cao, W., Nakaya, H. I., Teuwen, D., Pirani, A., Gernert, K., Deng, J., Marzolf, B., Kennedy, K., Wu, H., Bennouna, S., Oluoch, H., Miller, J., Vencio, R. Z., Mulligan, M., Aderem, A., Ahmed, R., & Pulendran, B. (2009). Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nature Immunology, 10, 116-125.
Li, C., Lee, A., Grigoryan, L., Arunachalam, P. S., Scott, M. K. D., Trisal, M., Wimmers, F., Sanyal, M., Weidenbacher, P. A., Feng, Y., Adamska, J. Z., Valore, E., Wang, Y., Verma, R., Reis, N., Dunham, D., O'hara, R., Park, H., Luo, W., … Pulendran, B. (2022). Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nature Immunology, 23, 543-555.
Pegu, A., O'connell, S. E., Schmidt, S. D., O'dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., Flach, B., Jackson, L., Leav, B., Ledgerwood, J. E., Luke, C. J., Makowski, M., Nason, M. C., Roberts, P. C., Roederer, M., … Shi, P.-Y. (2021). Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science, 373, 1372-1377.
Lustig, Y., Gonen, T., Meltzer, L., Gilboa, M., Indenbaum, V., Cohen, C., Amit, S., Jaber, H., Doolman, R., Asraf, K., Rubin, C., Fluss, R., Mendelson, E., Freedman, L., Regev-Yochay, G., & Kreiss, Y. (2022). Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose. Nature Immunology, 23, 940-946.
Goel, R. R., Painter, M. M., Lundgreen, K. A., Apostolidis, S. A., Baxter, A. E., Giles, J. R., Mathew, D., Pattekar, A., Reynaldi, A., Khoury, D. S., Gouma, S., Hicks, P., Dysinger, S., Hicks, A., Sharma, H., Herring, S., Korte, S., Kc, W., Oldridge, D. A., … Wherry, E. J. (2022). Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell, 185, 1875-1887.e8.
Ritchie, H., Mathieu, E., Rodés-Guirao, L., Appel, C., Gavrilov, D., Giattino, C., Hasell, J., Macdonald, B., Dattani, S., Beltekian, D., Ortiz-Ospina, E., & Roser, M. (2020). Coronavirus pandemic (COVID-19). Our World Data.
Wragg, K. M., Lee, W. S., Koutsakos, M., Tan, H.-X., Amarasena, T., Reynaldi, A., Gare, G., Konstandopoulos, P., Field, K. R., Esterbauer, R., Kent, H. E., Davenport, M. P., Wheatley, A. K., Kent, S. J., & Juno, J. A. (2022). Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory. Nature Immunology, 23, 768-780.
Tan, H.-X., Jegaskanda, S., Juno, J. A., Esterbauer, R., Wong, J., Kelly, H. G., Liu, Y., Tilmanis, D., Hurt, A. C., Yewdell, J. W., Kent, S. J., & Wheatley, A. K. (2019). Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem. Journal of Clinical Investigation, 129, 850-862.
Mclellan, J. S., Yang, Y., Graham, B. S., & Kwong, P. D. (2011). Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. Journal of Virology, 85, 7788-7796.
Swanson, K. A., Settembre, E. C., Shaw, C. A., Dey, A. K., Rappuoli, R., Mandl, C. W., Dormitzer, P. R., & Carfi, A. (2011). Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proceedings of the National Academy of Sciences of the United States of America, 108, 9619-9624.
Mclellan, J. S. (2015). Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Current Opinion in Virology, 11, 70-75.
Gilman, M. S. A., Castellanos, C. A., Chen, M., Ngwuta, J. O., Goodwin, E., Moin, S. M., Mas, V., Melero, J. A., Wright, P. F., Graham, B. S., Mclellan, J. S., & Walker, L. M. (2016). Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Science Immunology, 1, eaaj1879.
Simões, E. A. F., Center, K. J., Tita, A. T. N., Swanson, K. A., Radley, D., Houghton, J., Mcgrory, S. B., Gomme, E., Anderson, M., Roberts, J. P., Scott, D. A., Jansen, K. U., Gruber, W. C., Dormitzer, P. R., & Gurtman, A. C. (2022). Prefusion F protein-based respiratory syncytial virus immunization in pregnancy. New England Journal of Medicine, 386, 1615-1626.
Pfizer. Pfizer announces start of phase 3 clinical trial in adults for its investigational vaccine against respiratory syncytial virus (RSV). (2021). https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-start-phase-3-clinical-trial-adults-its
GSK. GSK starts phase 3 study of RSV maternal candidate vaccine. (2020). https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-3-study-of-rsv-maternal-candidate-vaccine/
Battles, M. B., Más, V., Olmedillas, E., Cano, O., Vázquez, M., Rodríguez, L., Melero, J. A., & Mclellan, J. S. (2017). Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein. Nature Communications, 8, 1528.
Hsieh, C.-L., Rush, S. A., Palomo, C., Chou, C.-W., Pickens, W., Más, V., & Mclellan, J. S. (2022). Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins. Nature Communications, 13, 1299.
Iketani, S., Liu, L., Guo, Y., Liu, L., Chan, J. F.-W., Huang, Y., Wang, M., Luo, Y., Yu, J., Chu, H., Chik, K. K.-H., Yuen, T. T.-T., Yin, M. T., Sobieszczyk, M. E., Huang, Y., Yuen, K.-Y., Wang, H. H., Sheng, Z., & Ho, D. D. (2022). Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature, 604, 553-556.
Kaku, C. I., Bergeron, A. J., Ahlm, C., Normark, J., Sakharkar, M., Forsell, M. N. E., & Walker, L. M. (2022). Recall of pre-existing cross-reactive B cell memory following Omicron BA.1 breakthrough infection. Science Immunology, 7, eabq3511.
Baral, P. K., Swayampakula, M., Aguzzi, A., & James, M. N. G. (2015). X-ray structural and molecular dynamical studies of the globular domains of cow, deer, elk and Syrian hamster prion proteins. Journal of Structural Biology, 192, 37-47.
Spagnolli, G., Rigoli, M., Orioli, S., Sevillano, A. M., Faccioli, P., Wille, H., Biasini, E., & Requena, J. R. (2019). Full atomistic model of prion structure and conversion. PLoS Pathogens, 15, e1007864.
Yamey, G., Garcia, P., Hassan, F., Mao, W., Mcdade, K. K., Pai, M., Saha, S., Schellekens, P., Taylor, A., & Udayakumar, K. (2022). It is not too late to achieve global covid-19 vaccine equity. BMJ, 376, e070650.
Rydland, H. T., Friedman, J., Stringhini, S., Link, B. G., & Eikemo, T. A. (2022). The radically unequal distribution of Covid-19 vaccinations: A predictable yet avoidable symptom of the fundamental causes of inequality. Humanities and Social Sciences Communications, 9, 1-6.
Hotez, P. J., & Ferris, M. T. (2006). The antipoverty vaccines. Vaccine, 24, 5787-5799.
Hayman, B., & Pagliusi, S. (2020). Emerging vaccine manufacturers are innovating for the next decade. Vaccine X, 5, 100066.
Thuluva, S., Paradkar, V., Gunneri, S., Yerroju, V., Mogulla, R. R., Suneetha, P. V., Turaga, K., Kyasani, M., Manoharan, S. K., Adabala, S., Javvadi, A. S., Medigeshi, G., Singh, J., Shaman, H., Binayke, A., Zaheer, A., Awasthi, A., Narang, M., Nanjappa, P., … Pandey, A. K. (2022). Safety, tolerability and immunogenicity of Biological E's CORBEVAXTM vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study. Vaccine, 40(49), 7130-7140.
Thuluva, S., Paradkar, V., Turaga, K., Gunneri, S. R., Yerroju, V., Mogulla, R., Suneetha, P. V., Kyasani, M., Manoharan, S. K., Adabala, S., Javvadi, A. S., Medigeshi, G., Singh, J., Shaman, H., Binayke, A., Zaheer, A., Amit, A., Singh, C., Rao, A. V., … Pandey, A. K. (2022). Immunogenic superiority and safety of Biological E's CORBEVAXTM vaccine compared to COVISHIELDTM (ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter, randomized clinical trial. https://doi.org/10.1101/2022.03.20.22271891
Chen, W.-H., Wei, J., Kundu, R. T., Adhikari, R., Liu, Z., Lee, J., Versteeg, L., Poveda, C., Keegan, B., Villar, M. J., De Araujo Leao, A. C., Rivera, J. A., Gillespie, P. M., Pollet, J., Strych, U., Zhan, B., Hotez, P. J., & Bottazzi, M. E. (2021). Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. Biochimica et Biophysica Acta, General Subjects, 1865, 129893.
Lee, J., Liu, Z., Chen, W.-H., Wei, J., Kundu, R., Adhikari, R., Rivera, J. A., Gillespie, P M., Strych, U., Zhan, B., Hotez, P J., & Bottazzi, M. E. (2021). Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1. Applied Microbiology and Biotechnology, 105, 4153-4165.
Hotez, P. J. (2021). Mounting antiscience aggression in the United States. PLoS Biology, 19, e3001369.
Hotez, P. J. (2021). Anti-science kills: From Soviet embrace of pseudoscience to accelerated attacks on US biomedicine. PLoS Biology, 19, e3001068.
Wood, D., & Brumfiel, G. (2022). Pro-Trump counties continue to suffer far higher COVID death tolls. NPR.
Macdonald, N. E., & SAGE Working Group on Vaccine Hesitancy. (2015). Vaccine hesitancy: Definition, scope and determinants. Vaccine, 33, 4161-4164.
Ten health issues WHO will tackle this year. (2019). https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019
Stojanovic, J., Boucher, V. G., Gagne, M., Gupta, S., Joyal-Desmarais, K., Paduano, S., Aburub, A.-S., Sheinfeld Gorin, S N., Kassianos, A. P., Ribeiro, P. A. B., Bacon, S. L., & Lavoie, K. L. (2021). Global trends and correlates of COVID-19 vaccination hesitancy: Findings from the iCARE study. Vaccines, 9, 661.
Solís Arce, J. S., Warren, S. S., Meriggi, N. F., Scacco, A., Mcmurry, N., Voors, M., Syunyaev, G., Malik, A. A., Aboutajdine, S., Adeojo, O., Anigo, D., Armand, A., Asad, S., Atyera, M., Augsburg, B., Awasthi, M., Ayesiga, G. E., Bancalari, A., Björkman Nyqvist, M., … Omer, S. B. (2021). COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nature Medicine, 27, 1385-1394.
Betsch, C., Schmid, P., Heinemeier, D., Korn, L., Holtmann, C., & Böhm, R. (2018). Beyond confidence: Development of a measure assessing the 5C psychological antecedents of vaccination. PLoS ONE, 13, e0208601.
De Figueiredo, A., Simas, C., Karafillakis, E., Paterson, P., & Larson, H. J. (2020). Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: A large-scale retrospective temporal modelling study. Lancet, 396, 898-908.
Leigh, J. P., Moss, S. J., White, T. M., Picchio, C. A., Rabin, K. H., Ratzan, S. C., Wyka, K., El-Mohandes, A., & Lazarus, J. V. (2022). Factors affecting COVID-19 vaccine hesitancy among healthcare providers in 23 countries. Vaccine, 40, 4081-4089.
Quinn, S. C., & Andrasik, M. P. (2021). Addressing vaccine hesitancy in BIPOC communities - Toward trustworthiness, partnership, and reciprocity. New England Journal of Medicine, 385, 97-100.
Dubé, E., & Macdonald, N. E. (2022). COVID-19 vaccine hesitancy. Nature Reviews Nephrology, 18, 409-410.
Jarrett, C., Wilson, R., O'leary, M., Eckersberger, E., & Larson, H. J. (2015). Strategies for addressing vaccine hesitancy - A systematic review. Vaccine, 33, 4180-4190.
Ryan, J., & Malinga, T. (2021). Interventions for vaccine hesitancy. Current Opinion in Immunology, 71, 89-91.
Singh, P., Dhalaria, P., Kashyap, S., Soni, G. K., Nandi, P., Ghosh, S., Mohapatra, M. K., Rastogi, A., & Prakash, D. (2022). Strategies to overcome vaccine hesitancy: A systematic review. Systematic Reviews, 11, 78.